SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Tuesday reported a loss of $37.6 million in its first quarter.
On a per-share basis, the San Diego-based company said it had a loss of 32 cents.
The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 39 cents per share.
The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.6 million in the period.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
